Hi [[ session.user.profile.firstName ]]

Forensic Science

  • A Risk Adaptive Approach to Data Protection
    A Risk Adaptive Approach to Data Protection
    Karlene Berger, Director Product Marketing Recorded: Sep 18 2019 9 mins
    Are You Taking a Risk-Adaptive Approach to Dynamic Data Protection?
    Why are data loss events increasing even while Cybersecurity spending is soaring? Because legacy DLP solutions are still focused on traditional threat blocking policies and haven't evolved to address today's modern security threats.

    Learn more about how taking a risk-adaptive approach combined with behavioral analytics can enable your security to fluctuate based on the threat environment.
  • Launch excellence in a disrupted world – challenges & opportunities
    Launch excellence in a disrupted world – challenges & opportunities
    Yasemin Karanis, Sarah Rickwood, Alexandra Smith, Markus Gores, IQVIA, Bill McClellan, IQVIA, Paul Tunnah, pharmaphorum Recorded: Sep 11 2019 70 mins
    Overview

    The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care to specialty launch, but its future will be transformed even more radically.

    The advent of highly novel cell and gene therapies as well as prescription digital therapeutics is providing a serious set of forces for change in the market.

    Another comes from the challenges developed markets face, which renews the urgency for pharma companies to spread their launch successes beyond traditionally core markets.

    The pressures exerted by these forces require companies’ efforts in launch excellence to be able to ‘square the circle’ of better launch returns even as the launch environment becomes ever-more complex.

    To make sense of this landscape, this pharmaphorum webinar – in association with IQVIA – will look at the past, present and future of pharmaceutical launches. The event takes place on Wednesday 11th September from 11:00-12:00 BST.

    Focus
    •Traditional launch approaches: In the past, launch was defined as being the first two years of a product’s existence on the market. This is still a crucial time for any product’s launch, however, in an increasingly multi-indicational world, for many products, launch is no longer a one-off event.

    •Current best practice in launch: Which launches have been the most commercially successful in recent years? By using IQVIA data the webinar will provide a unique view of the way in which commercial success has changed and look at what has driven the high-fliers.

    •Future of launch excellence. The nature of innovation is changing very rapidly, and with it, both what is defined as launch, and the key capabilities and resources required for excellent launches. IQVIA experts will outline how to prepare for the future of launch excellence.
  • Build my knowledge
    Build my knowledge
    Dr. Lara Dick,Dr. Lukasz Porwol and Virginia Ballance. Moderated by Rachel Brennesholtz Recorded: Sep 10 2019 47 mins
    For a researcher, building knowledge is a complex and time-consuming process: finding and evaluating the relevance of information is only the first step; then comes the need to properly collect, organize, retrieve and use literature and data to create a true knowledgebase.
  • Innovative contracting in Europe – a Trojan horse?
    Innovative contracting in Europe – a Trojan horse?
    Smita Sealey and Barry Farimond, ZS Associates, Malcolm Qualie, NHS England, Alain Boulanger, Filippo Drago Recorded: Sep 2 2019 64 mins
    Overview

    With pricing of drugs at the centre of political and social debate, the market access and pricing environment in Europe has become increasingly challenging over the years. Innovative contracting has since become a common route to overcome these challenges and ensure timely access for patients.


    Focus

    Join us on Monday 2nd September from 15:00-16:00 BST as we discuss the future of innovative contracting with our panel of European payers. Key topics to be covered include:

    To what extent and how contracting helps improve patient access?
    What prior successes and failures can teach us about designing contracts that deliver true value to the health systems?
    Can we avoid contracting and what would be the alternative?

    In the past decade, we have moved from simple discounting and traditional volume-based agreements to more complex value-based models involving measurement of health outcomes, risk-sharing and cost containment guarantees. The feasibility of these contracts tends to vary by EU market, dependent mainly on the available healthcare system infrastructure to collect and process data as well as other regulatory and philosophical differences.

    Ultimately, the question remains as to whether these agreements are a move towards better healthcare provision and more connected healthcare infrastructures, or are they slowing down access and creating administrative burden due to their complexity?
  • How pharma marketing can stay ahead of the evolving customer journey
    How pharma marketing can stay ahead of the evolving customer journey
    Robb DeFilippis, Managing Director, Life Sciences, Tag, Steve Pitts, Business Director, Tag, Dominic Tyer, pharmaphorum Recorded: Jul 23 2019 64 mins
    Overview
    Join our live webinar taking place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST.

    Customer journeys in pharma are changing, with important implications for the marketing supply chain. How can pharmaceutical marketers capitalise on this trend and free up budget to invest in additional marketing channels?

    Focus
    New developments in data and digital are changing traditional customer journeys and forcing pharmaceutical companies to evolve in order to keep up.

    Companies like Apple and Amazon have elevated customer expectations for personalised content and interactions across multiple channels, in the process setting new standards for marketing. But, as they push the envelope, what are the implications for pharma’s work in customer engagement?

    This pharmaphorum webinar, in association with Tag, will examine the challenges that pharma marketing faces to stay ahead of the evolving customer journey and offer expert insight from both the pharma and FMCG sectors on how to convert these challenges into opportunities .

    The expert panel will consider exclusive research carried out by Tag and pharmaphorum across the US, Europe and Asia-Pacific among senior decision-makers in pharma and FMCG marketing.

    The webinar, which takes place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST will also look at:
    •How pharma currently allocates its marketing budgets
    •Where marketers would like to have more money to invest
    •How much time is spent directing creative ideation and managing marketing production

    For more information, please visit:
    https://pharmaphorum.com/digital/how-pharma-marketing-can-stay-ahead-of-the-evolving-customer-journey/
  • Pharmaceutical Forensics for Safe Manufacturing and Supply
    Pharmaceutical Forensics for Safe Manufacturing and Supply
    Ravi Kalyanaraman and Jeremy Peters of BMS and Robert Heintz of Thermo Fisher Scientific Recorded: Jun 14 2019 74 mins
    by Ravi Kalyanaraman, Director at BMS

    Pharmaceutical Investigations and Technology (PIT) is a group within Global Analytical Technology (GAT) department in the commercial Quality organization within Bristol-Myers Squibb. The PIT group has been a key part in BMS for 30 + years in providing analytical support for commercial manufacturing and in pharmaceutical forensics. This include particulate and foreign matter characterization in pharmaceutical products and screening counterfeit drugs. Several analytical tools and techniques are used by PIT to support the pharmaceutical forensics.This talk will feature all the analytical techniques used by PIT and how the results are used in resolving manufacturing issues and to protect patients from counterfeit drugs.

    Followed by Why Use Raman Microscopy for Pharmaceutical Forensics?
    by Dr. Robert Heintz, Senior Applications Specialist at Thermo Fisher Scientific

    Raman microscopy is uniquely suited for providing essential information for pharmaceutical forensic applications. The use of visible lasers allows for analysis of very small samples with spatial resolutions down to a micron or better. Materials can be analyzed in glass containers and through transparent packaging. Mapping and imaging provides information on the spatial distribution of components as well as particle sizes and shapes. Confocal operation allows for probing inside transparent materials and analyze different layers or inclusions without the need to cut or cross-section the sample. Raman microscopy is non-destructive and preserves the sample for further analysis. Raman spectra can be used not only for the conformation of expected components but also the identification of unknown contaminants or impurities. Spectral features are very sensitive to molecular structure and can be used to distinguish polymorphs and other very chemically similar materials. All of these aspects of Raman microscopy make it an indispensable tool for pharmaceutical forensics.
  • Orphan medicines launch excellence: sustaining launch success
    Orphan medicines launch excellence: sustaining launch success
    Peter Meeus, European Orphan Medicines, Sarah Rickwood, IQVIA, Angela McFarlane, IQVIA, Paul Tunnah, pharmaphorum Recorded: Jun 13 2019 72 mins
    Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

    There are also a growing number of disease-focussed registries, increasing public and policy maker awareness, and significant R&D investment in orphan drugs, as well as in digital technologies to support trials and treatment.

    But a new frontier of challenge faces orphan medicines companies as the gap between orphan medicines and mainstream specialty products narrows.

    To understand how to succeed in launching an orphan medicine in the coming years, companies must learn from past launches and apply an orphan medicines-focused launch excellence framework for success.

    This internationally relevant webinar will provide US and European examples to illustrate the ways in which the pharmaceutical market for orphan medicines is changing and how, consequently, launch strategies must evolve.

    This pharmaphorum debate, held in partnership with IQIVA, will also look at how pharmaceutical companies can optimise all the activities needed to take orphan medicines from clinical development to commercialisation, including:

    •Identifying the three fundamental challenges for orphan medicine launch excellence
    •Discussing the ways in which companies launching orphan medicines can learn from excellence in mainstream launches
    •Examining, in-depth, the specific areas of focus which are crucial for orphan medicines excellence.
  • Introduction to Mendeley for Reference Management
    Introduction to Mendeley for Reference Management
    Rachel Brennesholtz, Community Marketing Manager Recorded: May 16 2019 45 mins
    Mendeley is a free reference manager and academic social network that can help you organize your research, easily create a bibliography, collaborate with others online, and discover the latest research. We will be having an introductory session covering Mendeley's main features. This online presentation is free to register and will run for approximately forty-five minutes.
  • Employing a Risk Adaptive Model to Detect and Prevent Threats From Within
    Employing a Risk Adaptive Model to Detect and Prevent Threats From Within
    Homayun Yaqub, Sr. Director Security Strategist, Forcepoint Recorded: May 8 2019 23 mins
    As we enable employees to be more productive with greater access to critical data, we also increase the risk of a potential breach due to accidental or malicious insider activity.

    Striking a balance between maximizing productivity and minimizing risk requires a security program that can identify and respond to the insider threat. In this webcast Forcepoint Senior Security Strategist Homayun Yaqub, discusses the foundations that underpin an effective program, including:

    - Refining analytics to better understand the intersection between people and data
    - Operationalizing CARTA as the next step in insider threat program development
    - Addressing insider risk as a core business concern
  • Navigating new frontiers: Ways to find space in the future RA market
    Navigating new frontiers: Ways to find space in the future RA market
    Helen Parfitt, Head of Therapy Watch, Research Partnership, Mariel Metcalfe and Mark Hollis, Research Partnership Recorded: Mar 21 2019 52 mins
    Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).

    The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

    Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

    Analysis of Therapy Watch data, a real-time' syndicated market tracking tool from Research Partnership, shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

    This pharmaphorum webinar, held in conjunction with Research Partnership, will use the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

    This webinar will provide an opportunity to interact with the panel about how companies can best harness the potential of this increasingly complex, but highly rewarding, market.

    Topics to be covered include:

    The European RA market
    Current status and market situation of JAK inhibitors (key EU5 countries)
    Uptake curve of JAKs compared to other new entrants and biosimilars
    Profile of physicians prescribing JAKS
    Country differences
    The future of new classes of JAK inhibitors
  • Discoverable Research Workflows
    Discoverable Research Workflows
    Trish Wilgar, SSRN Recorded: Mar 7 2019 22 mins
    Introducing the Mendeley Data datasets API on SSRN! Learn more about early stage research and the integration of Mendeley Data datasets on SSRN encourages authors to upload the research data associated with their papers, allowing for greater transparency and reproducibility. SSRN authors get the credit for their research outputs, attract more citations, compliance with funder mandates data sharing, and more. SSRN readers easily access the data, can evaluate and follow the data connections, and use the data to create individual research.
  • Sharpshooters Guide to Troubleshooting IHC
    Sharpshooters Guide to Troubleshooting IHC
    Ourhay Shamoon Recorded: Feb 27 2019 66 mins
    Come one, come all to the troubleshooting gallery as we learn sure-fire techniques to troubleshoot IHC stains. Inappropriate stains impact patient care, slow your lab down, and waste reagents, all of which cost your lab money, time, and peace of mind. This workshop will cover common histology and immunohistochemistry protocols, paying close attention to how each step influences stain quality. We’ll take aim at the root cause for most stain issues and set our sights on the red flags to look for when troubleshooting. We’ve got you covered from specimen collection to cover slipping. Too Light, Too Dark, Background, No Stain and the rest of the outlaws won’t stand a chance. You’ll mosey out of this workshop with a thorough understanding of how histology and immunohistochemistry work to produce a quality stain and the tools you will need to efficiently troubleshoot the most common stain issues. Giddy up and count yourself among the ranks of ‘Sharp Troubleshooter’ for your lab.
  • Just What the Dr Ordered for UK Life Sciences? The 2nd Life Sciences Sector Deal
    Just What the Dr Ordered for UK Life Sciences? The 2nd Life Sciences Sector Deal
    Erik Nordkamp, GM UK, Pfizer, Dr Keri Torney, Deputy Director Life Sciences, NHS England, Angela McFarlane, IQVIA Recorded: Feb 7 2019 73 mins
    Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS.

    With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.

    This pharmaphorum webinar, held in partnership with IQVIA, will analyse the current and future landscape for UK life sciences as well as what steps have been taken so far to boost the sector.

    Panellists from across the industry will look at the challenges presented by the current situation with Brexit and how the 10-Year Plan and the Sector Deal 2 (or 2018) play into this. They will discuss the positive steps taken by the government to prepare NHS innovation for a radically different future and make sure the UK remains an attractive location for ongoing inward investment from global pharma.

    Topics to be covered include:

    •Highlights of the 10-Year Plan and the second Sector Deal
    •Progress with the current Life Sciences Industrial Strategy, the Sector Deal and plans for 2019
    •The NHS innovation uptake agenda
    •Maintaining UK attractiveness for inward global pharma and biotech investment
  • Cancer, genomics and personalised medicine: Modelling the future of oncology
    Cancer, genomics and personalised medicine: Modelling the future of oncology
    Danyi Wen, Shanghai LIDE Biotech, Stefan Jellbauer, Mitra Biotech, Lakshmi Santhosh Maithel, Repositi Recorded: Jan 29 2019 61 mins
    The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in 2 people in the UK and 1 in 2 men/1 in 3 women in the US will experience it at some stage in their lives. And yet the picture for patients is an improving one.

    The move towards immunotherapies heralds much promise and this is potentially just the beginning. As cancer is understood increasingly not by type, or even tumour type but specific mutation the era of personalised oncological therapies is visible.
    To delve further into this pharmaphorum is pleased to present an exclusive online discussion.

    Bringing together experts at the cutting edge of this field it aims to interrogate where we are in terms of this shift towards personalised oncology, what this means in terms of the development pathway and looks at the approaches which could (and will) fully evolve the way that cancer treatments are developed in terms of efficacy, approach and outcome.

    this free to attend event will cover a number of topics critical to the future of oncology including:
    •The changing face of cancer: how do we define it now?
    •Personalised medicine in practice – where are we now in cancer?
    •What are the implications from these changes for clinical trials?
    •How the shift towards cancer as a phenotype/genotype is being applied in clinical trials and how they are run
    •What are co-clinical trials and why could they hold the key to answering unmet need in cancer treatment and beyond into broader drug development?
    •Modelling for the future of cancer – can this be done for personalised therapies?
  • Metrics to meaning: demonstrating the value of medical communications
    Metrics to meaning: demonstrating the value of medical communications
    Scott McGregor, Allergan, Lynda Chang, Complete HealthVizion, David Pearce, Complete HealthVizion, Dominic Tyer, pharmaphorum Recorded: Jan 23 2019 62 mins
    Medical affairs and publications teams are under increasing pressure to demonstrate effectively the success of the medical communications activities they undertake.

    Naturally, there are a huge number of metrics that could be used to measure and demonstrate medical communications value. The challenge is to identify, and track, those metrics that really matter, and ensure this information is interpreted effectively.

    This pharmaphorum webinar, which will be held in partnership with Complete HealthVizion, will look at how to measure medical communications activities, how to continue with what is successful and how to change what isn’t working.

    This means identifying what can be measured, both in terms of reach and engagement as well as behavioural impact, deciding what ‘great’ looks like and how best to define success.

    The expert panel will also look at how behavioural science can provide a framework to develop smarter communications and, ultimately, drive better patient outcomes.

    This Metrics to Meaning webinar will take place on Wednesday, 23rd January, at 15:00 pm GMT (10:00 EST) and will teach you how to measure the effectiveness of different types of medical communications programmes.

    Interacting with the panel will also allow you to learn about a range of practical approaches to implementing metrics, including:

    • Innovative ways to measure medical communications value and success
    • How to help medical affairs and publications teams demonstrate greater value
    • How to optimise tactical outputs year on year
    • The importance of demonstrating and measuring behavioural change

    In doing so they will also discuss the role of behaviour and the implications of this for measuring success.
  • Researcher Academy: An introduction to e-learning resources for researchers
    Researcher Academy: An introduction to e-learning resources for researchers
    Priyanka Kalra Recorded: Jan 22 2019 33 mins
    Researcher Academy (https://researcheracademy.elsevier.com/) provides free access to countless e-learning resources designed to support researchers on every step of their research journey. Browse our extensive module catalogue to uncover a world of knowledge, and earn certificates and rewards as you progress.
  • How Researchers & Publishers Can Collaborate In The Move Towards Open Science
    How Researchers & Publishers Can Collaborate In The Move Towards Open Science
    Moderated by Stephane Berghmans, Director Academic Relations, Elsevier Recorded: Jan 21 2019 89 mins
    A debate on challenges and opportunities in open access & open data
  • The devil’s in the e-detail: what HCPs really want from you
    The devil’s in the e-detail: what HCPs really want from you
    Heiko Schmidt, Integrated Multichannel Marketing and Sales, Bayer, Sari Ruth Carter, Head of Marketing, Anthill Agency Recorded: Dec 6 2018 68 mins
    Overview:
    Communication; we all do it, it is a critical part of effective business practice and in this pharma is no exception.

    It is no secret that for pharma companies, face time with healthcare professionals (HCPs) has reduced drastically over the last 10 years while the cost of in person engagements has increased significantly.

    Like any customer their expectations for the content they receive have changed, with a focus on useful, succinct and easy to consume materials rather than the sales materials of old.

    So what is it that HCPs want and through this lens, what is it that pharma should be doing?

    The evidence points towards creating meaningful two-way conversations through multiple channels, connecting otherwise siloed touchpoints with and for HCPs in the process.

    For the past 40 years detailing has been the backbone of pharma/HCP communication – but what about e-Detailing? Is it just detailing on an ipad or is it supposed to be something more? How does this fit and what is possible, and more importantly desirable?

    To analyse the current situation and present practical insights, pharmaphorum presents a new free to attend digital debate. Working with our partner Anthill agency we have put together a panel of leading experts from Bayer and Anthill.

    This debate will cover:

    •What is the current landscape for optimal HCP communication?
    •What is the future in terms of HCP channel preference?
    •New technologies in pharma marketing that help you to better engage with HCPs and extend HCP reach – AI, chatbots, self-detailing
    •How to reach more HCPs, when, where and how they want
    •How to overcome low content usage by HCPs
    •The most common challenges for traditional eDetailing effectiveness
    •How to achieve better communication without having to reinvent the wheel
    •How to activate your existing content and reach all customers willing to engage with your brand, regardless of their preference.
  • Can simulated datasets unlock the potential of patient data?
    Can simulated datasets unlock the potential of patient data?
    Jem Rashbass, Health Data Insight, Chris Carrigan, use MY data, Adam Reich, IQVIA, Dominic Tyer, pharmaphorum Recorded: Nov 27 2018 68 mins
    Patient level data offers the promise of insights which can craft new and better pathways, enable development of innovative therapies and treatments, and of course identify and prevent diseases much earlier in their lifecycle.

    One area of particular interest is cancer. However, in trying to realise the potential, the health sector is faced with the conundrum of protecting patients’ identities, while at the same time allowing doctors access to their data and enabling industry to benefit from vital insights into the disease.

    This presents a paradox, as the UK has some of the best healthcare data in the world, however, accessing the data can be challenging and time consuming due to patient confidentiality checks.

    So, what is the solution?

    IQVIA brings a unique perspective to this event, having partnered with Health Data Insight to develop an innovative solution to this seemingly intractable problem: Simulacrum, a database comprised of only artificial data that is modelled on real patient data collected by the National Cancer Registration and Analysis Service (NCRAS) in England.

    Simulacrum has already produced identical results to the real data when predicting incidence of tumours in the population, whilst simultaneously removing any risk of breaching patient confidentiality.

    In this webinar, IQVIA and pharmaphorum will also provide advice to industry, patient advocacy groups and healthcare professionals on how to leverage Simulacrum, and utilise this simulated dataset to facilitate access to England’s world-leading healthcare data, while complying with regulations designed to protect and maintain individual confidentiality.
  • Digital therapeutics and healthcare innovation
    Digital therapeutics and healthcare innovation
    Roberto Ascione, Healthware International, Megan Coder, Digital Therapeutics Alliance, Pierre Leurent, Voluntis Recorded: Oct 12 2018 70 mins
    Digital technology is transforming the way that healthcare is practiced and delivered, with areas like digital therapeutics forging ahead to complement traditional medical approaches and augment patient care.

    The development of software applications that are available with a prescription took a major step forward last year with the first FDA approval for a mobile medical application with both a safety and efficacy label.

    At the same time as digital therapeutics are breaking new ground there’s a whole ecosystem of digital health innovations that are also tackling healthcare issues in new and imaginative ways.

    From doctor-patient communication to managing healthcare costs, from healthcare monitoring to clinician workflow, the range of digital health tools and services available is rapidly expanding.

    We’ll be looking at how digital and traditional approaches to medicine are being combined to improve patient outcomes.

    This free webinar will also see our expert panel:
    •Consider the current state of play with digital therapeutics and what the future holds for them
    •Discuss how to harness healthcare innovations to involve and engage patients
  • Realising the biotech promise: addressing the path to market
    Realising the biotech promise: addressing the path to market
    Steve Bates, BIA, Sheela Upadhyaya, NICE, Fred Jacobs, TYG, Dean Summerfield, IQVIA Recorded: Oct 9 2018 72 mins
    Now more than ever before, Biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.

    The journey from molecule discovery and development through valuation, funding, regulatory and commercialisation can be a long and complex road to travel though.

    These companies have to navigate a rapidly changing and increasingly complex landscape from pre-clinical valuation through foresight and planning at every stage of the asset life cycle - and at a time when Brexit adds uncertainty about regulatory approval and launch windows.

    Working with IQVIA, pharmaphorum has assembled a specialist panel to discuss these challenges and the most effective routes to overcoming them.

    On Tuesday 9th October at 15:00 BST / 10:00 EST we will present a free-to-attend online debate which will bring these experts together to deliver insight on topics such as market valuation, financing, navigating regulatory hurdles, patient engagement & HTA strategies through to successful commercialisation.
  • A full overview of different technologies to increase HPLC efficiency & speed
    A full overview of different technologies to increase HPLC efficiency & speed
    Dr. Frank Michel, Analytical & Chromatography Scientific Advisor, Merck KGaA, Darmstadt, Germany Recorded: Oct 4 2018 64 mins
    In the recent decades the demand for higher separation efficiency or higher speed in HPLC has increased strongly. The response to this demand was answered by modern HPLC technologies such as UHPLC with sub-2 µm particles, monolithic silica or Fused-Core™ particles. This webinar provides an overview on the factors that influence the speed of the HPLC method. It introduces the different approaches of small HPLC particles, Fused-Core (also known as core-shell) particle technology and monolithic silica rods and discusses the advantages and disadvantages of each approach. The presentation covers the theoretical background of these technologies and multiple examples of applications.
  • 爱思唯尔卓越科研在线讲座:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    爱思唯尔卓越科研在线讲座:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    Helena Wang Recorded: Sep 6 2018 64 mins
    与《柳叶刀》亚洲区执行主编王辉(Helena Wang)女士一起学习在高影响力期刊上发表论文的技巧和策略。王辉女士将分享她在整个研究论文发表周期中与研究人员和论文作者合作的经验,介绍如何撰写能够在优质出版物上发表的论文,以及广泛传播研究成果的机会。本次在线研讨会内容精彩纷呈,不容错过,能够让您的研究过程和研究影响再上新台阶。This webinar will be in Mandarin (Chinese).
  • Engaging with HCPS: what do HCPs want from medical meetings?
    Engaging with HCPS: what do HCPs want from medical meetings?
    Aoife Delmas, European Society of Cardiology, Katie Koziol and Andrew Moore, Ashfield Meetings & Events Recorded: Jun 26 2018 65 mins
    There has been a myriad of reasons over the past few years to safely assume the popularity and perceived worth of face-to-face medical meetings was well and truly on the decline – from advances in technology, to funding challenges.

    Separate, yet complementary studies looking at global HCP preferences reveals that the medical meeting is in fact their preferred channel for scientific communications.

    Yet a 2018 study by Ashfield looking at global HCP preferences reveals that the medical meeting is in fact their preferred channel for scientific communications.

    Furthermore, HCPs exhibit consumer behaviours in selecting and attending events – which means that while these conferences offer potential engagement riches, they have to offer a specific mix of focus, value and ROI to be successful. To analyse this situation, discuss the learnings from the research and offer guidance on what a modern medical meeting needs to be we present an exclusive debate.

    Bringing together experts from Ashfield Meetings & Events and the European Society of Cardiology our panel will discuss:

    1. Findings from the 2018 Ashfield Science of HCP Meetings research and whitepaper
    2. How HCPs want to engage with pharma and scientific communications
    3. What works? How to create the events that HCPs want to attend
    4. The future of meetings - balancing face to face and digital
    5. How HCPs determine whether a meeting is likely to be worth the investment
    6. Strategies and tactics for planners and meeting stakeholders to implement to continue to add value for HCPs attending medical meetings
  • User Profiles Tutorial
    User Profiles Tutorial
    Kathleen Berryman Recorded: Jun 18 2018 4 mins
    A short tutorial showing how to create and use the user profiles feature in Cabells.
  • Unified Data Protection: Part 2
    Unified Data Protection: Part 2
    Ankur Chadda, Senior Product Marketing Manager Oct 16 2019 3:00 pm UTC 38 mins
    Enterprises are facing new challenges when it comes to protecting regulated data and critical IP.

    Understanding the location of all data, whether at-rest, in-use, and in motion across on-premises and the cloud is essential to keep data safe and secure. This enables companies to identify its riskiest users and behaviors. With Forcepoint, you can automate the identification, classification, and protection of critical data.

    Wednesday, October 16, 2019

    10 a.m. CDT

    This webinar explores how companies should rethink data security. Addressing the challenges of protecting critical data & intellectual property requires a new approach: a risk-adaptive, dynamic approach to data protection, including these three main components.

    Analytics-Driven Visibility – to gain oversight everywhere users work and collaborate

    Risk-Adaptive Controls – to eliminate the complexity of policy enforcement

    Intelligent & Dynamic Automation – to build a better understanding of context and user intent
  • 爱思唯尔卓越科研在线讲座重播:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    爱思唯尔卓越科研在线讲座重播:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    Helena Wang Nov 7 2019 3:00 am UTC 63 mins
    与《柳叶刀》亚洲区执行主编王辉(Helena Wang)女士一起学习在高影响力期刊上发表论文的技巧和策略。王辉女士分享了她在整个研究论文发表周期中与研究人员和论文作者合作的经验,介绍如何撰写能够在优质出版物上发表的论文,以及广泛传播研究成果的机会。本次研讨会内容精彩纷呈,不容错过,能够让您的研究过程和研究影响再上新台阶。This webinar is in Mandarin (Chinese).
  • Design of remote luminescent thermometers for bio-imaging
    Design of remote luminescent thermometers for bio-imaging
    Dr. Markus Suta, Utrecht University Oct 24 2019 1:00 pm UTC 60 mins
    Join Reaxys Prize Club member Dr. Markus Suta for fascinating insights into luminescence thermometry. In this webinar, he describes the development and validation of remote lanthanide-based luminescent thermometers with applications in bio-imaging. Discover why a combination of in silico modelling and wet-lab experiments were essential to the success of the project. Dr. Suta also talks about the importance of efficient literature research to his work.
  • Showcasing your research: Present the full picture of your research achievements
    Showcasing your research: Present the full picture of your research achievements
    Heather Williams Oct 29 2019 10:00 am UTC 30 mins
    This 30 minute webinar will discuss how Elsevier supports researchers by providing tools to effectively showcase their research profile and increase their visibility, a skill that is vital in the research world.
  • Cost & Management of Oncology Combination Regimens
    Cost & Management of Oncology Combination Regimens
    Marcia Palmer, Allen W. Becker, Anthony Chiefari, Howard Deutsch, Nicolle Hamilton, ZS Associates Oct 30 2019 2:00 pm UTC 90 mins
    Overview
    Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there are significant cost implications of combining high priced innovator drugs (versus older, generic chemotherapies).

    Payers are in a difficult spot regarding the cost and management of these regimens. Traditional utilization management tools are still difficult to apply in oncology, given no payer wants to be on the front page of a major newspaper for denying treatment. Pathways have not held up to their promise for containing cost.

    Personalized medicine approaches such as biomarkers serve an important role in targeting therapy to the most appropriate patients, thereby reigning in cost. However, there are limitations in the breadth and utility of these tools. For example, PD-1/PDL-1 drugs have shown conflicting outcomes associated with receptor expression – and these drugs are the backbone for many combo regimen programs in clinical development.

    Environment/perception shifts, new approaches to management, indication-based pricing or other novel pricing approaches, and innovative payment models may hold promise for controlling cost in this new era of combination therapy.

    Focus
    Join ZS Associates for a live expert payer panel discussion on the challenges and potential solutions for managing the cost of combo oncology regimens. Topics will include:

    •Perspectives on oncology drug management and combination regimen pricing today
    •Potential payer-driven and pharma-driven solutions to price and cost management for oncology combo regimens
    •What oncology manufacturers should consider in engaging payers in the future

    The live payer webinar, co-moderated by Nicolle Hamilton, ZS Associates and Dominic Tyer, pharmaphorum, will take place on Wednesday, October 30 2019 from 14:00-15:15 GMT/10:00-11:15 ET.
  • Pharmaceutical Forensics for Safe Manufacturing and Supply
    Pharmaceutical Forensics for Safe Manufacturing and Supply
    Ravi Kalyanaraman and Jeremy Peters of BMS and Robert Heintz of Thermo Fisher Scientific Nov 6 2019 6:00 am UTC 76 mins
    Why Use Raman Microscopy for Pharmaceutical Forensics?
    by Dr. Robert Heintz, Senior Applications Specialist at Thermo Fisher Scientific

    Raman microscopy is uniquely suited for providing essential information for pharmaceutical forensic applications. The use of visible lasers allows for analysis of very small samples with spatial resolutions down to a micron or better. Materials can be analyzed in glass containers and through transparent packaging. Mapping and imaging provides information on the spatial distribution of components as well as particle sizes and shapes. Confocal operation allows for probing inside transparent materials and analyze different layers or inclusions without the need to cut or cross-section the sample. Raman microscopy is non-destructive and preserves the sample for further analysis. Raman spectra can be used not only for the conformation of expected components but also the identification of unknown contaminants or impurities. Spectral features are very sensitive to molecular structure and can be used to distinguish polymorphs and other very chemically similar materials.

    Followed by Pharmaceutical Forensics for Safe Manufacturing and Supply
    by Ravi Kalyanaraman, Director at BMS

    Pharmaceutical Investigations and Technology (PIT) is a group within Global Analytical Technology (GAT) department in the commercial Quality organization within Bristol-Myers Squibb. The PIT group has been a key part in BMS for 30 + years in providing analytical support for commercial manufacturing and in pharmaceutical forensics. This include particulate and foreign matter characterization in pharmaceutical products and screening counterfeit drugs. Several analytical tools and techniques are used by PIT to support the pharmaceutical forensics.This talk will feature all the analytical techniques used by PIT and how the results are used in resolving manufacturing issues and to protect patients from counterfeit drugs.
  • Viral Safety by Design for Cell and Gene Therapy Products
    Viral Safety by Design for Cell and Gene Therapy Products
    Mark Plavsic, Chief Technology Officer at Lysogene & Archie Lovatt, Life Sciences Biosafety Scientific Director at SGS Nov 11 2019 2:00 am UTC 67 mins
    Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C&GT) biologics. Adventitious agents (viruses, bacteria, mycoplasma, prions, etc) pose constant risk to these biologics, and, as such they may impact directly product and patient safety. It is therefore of supreme importance to intentionally (by design) employ effective measures across the whole C&GT product manufacturing process to mitigate risk of adventitious agents. This presentation will review various interconnected steps throughout the manufacturing process, from the raw materials to the fill and finish, that would, in concert, help mitigate the risk while providing a high degree of product safety by design.